All News
Lupus Patients Genomically Stratified to Explain Treatment Responses
Systemic lupus is a clinically heterogeneous disorder, unified by requisite clinical features and exuberant humoral response to unknown triggers. While the diagnosis is easy, the disease course and management can be complicated and challenging.
Read ArticleEULAR 2016 Drug Safety Report
The EULAR Annual European Congress of Rheumatology meeting was held in London from June 8-11, 2016 and was well attended by thousands. This year’s meeting had over 2,000 poster displays, and the EULAR 2016 Congress presented new recommendations on the management of rheumatoid arthritis, spondyloarthritis, and fibromyalgia.
Read Article
Arthritis and Suicide Linked with Childhood Adversities
Men and women with arthritis have nearly a two-fold higher prevalence of lifetime suicide attempts than those without arthritis, according to a recent study from the University of Toronto.
Read ArticleJIA Women at Risk of Heart Disease
Women with a history of juvenile idiopathic arthritis (JIA) are more than twice as likely as those without this condition to be diagnosed with heart disease, according to the results of a new study.
Read Article
FDA Will Review Opioid Analgesic Use and REMS Programs for Pediatric Pain Patients
Amidst a stringent regulatory environment, and with the rising use and abuse of narcotics and increasing regulation limiting narcotic analgesic use, the FDA approved (August 2015) the use of extended-release oxycodone in children (11 to 16 years old) with severe, "around-the-clock" pain
Read ArticleRheumNow Week in Review - 15 April 2016
Video recap of highlights from this week at RheumNow.com.
Read ArticleLupus Patients Genomically Stratified to Explain Treatment Responses
Systemic lupus is a clinically heterogeneous disorder, unified by requisite clinical features and exuberant humoral response to unknown triggers. While the diagnosis is easy, the disease course and management can be complicated and challenging.
Read ArticleNovel Protein as a Potential Autoantigen in JIA
Juvenile idiopathic arthritis (JIA) is clearly not related to rheumatoid arthritis and until recently has no identifiabile autoantigen linked to JIA.
Read ArticleNew Classification Criteria for Macrophage Activation Syndrome
Systemic juvenile idiopathic arthritis (SoJIA) is one of the most common underlying etiologies to the macrophage activation syndrome (MAS).
Read ArticleChallenges of Dermatomyositis Progress
In the current issue of Lancet, Pierre Miossec discusses the challenges of studying and managing juvenile dermatomyositis and, specifically, the
Read ArticleRWCS 2016 – OA/OP, Gout, Sarcoid & JIA Reviewed
Recent Developments in Osteoarthritis, Osteoporosis and Gout
Read ArticleParenteral Methotrexate Intolerance is High in Juvenile Idiopathic Arthritis
Juvenile idiopathic arthritis (JIA) is commonly managed with methotrexate (MTX), with many pediatric rheumatologists preferring to use parenteral MTX for compliance and absorption reasons.
Read ArticleJuvenile Dermatomyositis Responds Best to Methotrexate and Prednisone
Lancet reports the results of a randomized controlled trial comparing prednisone alone to prednisone combined with either methotrexate (MTX) or cyclosporine (CyA) in new-onset juvenile dermatomyositis (JDM).
Read ArticleGenetic Basis for Pediatric Autoimmune Diseases
Researchers at CHOP have published their investigations into the heritability of pediatric autoimmune diseases that affects roughly one in 12 persons.
Read ArticleJIA Pathogenesis Related to Neutrophils and Epigenetics
Neutrophils are pivotal players in the innate immune response, but are seldom linked to the pathogenesis of inflammatory arthritis, including juvenile idiopathic inflammatory arthritis (JIA).
Read ArticleSerious Infections Increased in Etanercept-Treated Juvenile Arthritis Patients
UK researchers set out to study medically significant infections (MSI) in juvenile idiopathic arthritis patients enrolled in the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN).
Read ArticleThe EULAR 2015 Report – Friday and Saturday
These abstracts and presentations were presented last week on the 12th and 13th of June at the EULAR 2015 annual meeting in Rome.
Read ArticleHigh Flare Rates with Drug Withdrawal in JIA
While many adult rheumatologists are able to lessen or withdraw DMARD and biologic therapy in adults, little is known about the success of this practice in pediatric rheumatology clinics.
Read ArticleReal World Biologic Success in Systemic JIA
A retrospective review of 77 SoJIA patients revealed that 50-70% achieved inactive disease or remission when treated with IL-1 inhibitors (anakinra, canakinumab). Good responses were seen with tocilizumab or abatacept, but only 8% responded to etanercept.
Read Article